GlassScriptPhysician profile
Philip J Dunn
NPI 1962847772
$84,122.60
in general payments reported to CMS, 2019-2025
33 companies · $19K in 2025
The $19K reported for 2025 was more than what 92% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,584 · 2020: $4,648 · 2021: $6,300 · 2022: $11K · 2023: $22K · 2024: $17K · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $40K · Honoraria: $9,938 · Food and Beverage: $5,034 · Travel and Lodging: $3,186 · Education: $54.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $40,212.50 |
| Honoraria | $9,937.50 |
| Food and Beverage | $5,034.37 |
| Travel and Lodging | $3,186.46 |
| Education | $54.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $38,045.77 | 2019-2025 | Rinvoq, Skyrizi |
| Horizon Therapeutics Plc | $26,207.30 | 2019-2023 | Krystexxa |
| Amgen INC. | $13,100.55 | 2019-2025 | Krystexxa, Tavneos, Enbrel |
| Novartis Pharmaceuticals Corporation | $1,257.97 | 2019-2024 | |
| Ucb, INC. | $1,199.24 | 2019-2024 | Cimzia, Bimzelx |
| Pfizer INC. | $717.67 | 2019-2023 | |
| Alexion Pharmaceuticals, INC. | $404.93 | 2020-2024 | Strensiq |
| Janssen Biotech, INC. | $401.66 | 2019-2024 | Tremfya |
| Astrazeneca Pharmaceuticals LP | $398.85 | 2022-2023 | Saphnelo |
| Lilly USA, LLC | $360.65 | 2019-2022 | |
| Sobi, INC | $334.03 | 2019-2021 | |
| Glaxosmithkline, LLC. | $239.56 | 2019-2023 | Benlysta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $213.01 | 2019-2023 | Ofev |
| Janssen Scientific Affairs, LLC | $209.20 | 2019-2022 | |
| Celgene Corporation | $170.83 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $125.18 | 2021 | |
| Aurinia Pharma U.S., INC. | $118.21 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $99.60 | 2019 | |
| Genentech USA, INC. | $91.25 | 2019-2023 | Actemra |
| Radius Health, INC. | $86.33 | 2019-2021 | |
| Pacira Therapeutics, INC. | $72.12 | 2019 | |
| Genzyme Corporation | $43.65 | 2019 | |
| Ferring Pharmaceuticals INC. | $29.31 | 2022 | |
| Organon LLC | $27.69 | 2023 | Hadlima, Renflexis |
| Biohaven Pharmaceuticals, INC. | $27.00 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $24.03 | 2019-2020 | |
| Lexicon Pharmaceuticals, INC. | $21.44 | 2023 | Inpefa |
| Sandoz INC. | $18.98 | 2023 | Hyrimoz |
| Janssen Pharmaceuticals, INC | $17.81 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $16.23 | 2023 | Uptravi |
| Johnson & Johnson Health Care Systems INC. | $16.00 | 2022 | |
| Sanofi Pasteur INC. | $13.81 | 2020 | |
| Avion Pharmaceuticals | $12.74 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Dunn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.